Transgelin-2 as a therapeutic target for asthmatic pulmonary resistance

Lei Miao Yin, Yu Dong Xu, Ling Ling Peng, Ting Ting Duan, Jia Yuan Liu, Zhijian Xu, Wen Qian Wang, Nan Guan, Xiao Jie Han, Hai Yan Li, Yu Pang, Yu Wang, Zhaoqiang Chen, Weiliang Zhu, Linhong Deng, Ying Li Wu, Guang Bo Ge, Shuang Huang, Luis Ulloa, Yong Qing Yang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

There is a clinical need for new bronchodilator drugs in asthma, because more than half of asthmatic patients do not receive adequate control with current available treatments. We report that inhibition of metallothionein-2 protein expression in lung tissues causes the increase of pulmonary resistance. Conversely, metallothionein-2 protein is more effective than -2-agonists in reducing pulmonary resistance in rodent asthma models, alleviating tension in tracheal spirals, and relaxing airway smooth muscle cells (ASMCs). Metallothionein-2 relaxes ASMCs via transgelin-2 (TG2) and induces dephosphorylation of myosin phosphatase target subunit 1 (MYPT1). We identify TSG12 as a nontoxic, specific TG2-agonist that relaxes ASMCs and reduces asthmatic pulmonary resistance. In vivo, TSG12 reduces pulmonary resistance in both ovalbumin- and house dust mite-induced asthma in mice. TSG12 induces RhoA phosphorylation, thereby inactivating the RhoA-ROCK-MYPT1-MLC pathway and causing ASMCs relaxation. TSG12 is more effective than -2-agonists in relaxing human ASMCs and pulmonary resistance with potential clinical advantages. These results suggest that TSG12 could be a promising therapeutic approach for treating asthma.

Original languageEnglish (US)
Article numbereaam8604
JournalScience Translational Medicine
Volume10
Issue number427
DOIs
StatePublished - Feb 7 2018

Fingerprint

Smooth Muscle Myocytes
Lung
Metallothionein
Asthma
Myosin-Light-Chain Phosphatase
Therapeutics
Pyroglyphidae
Muscle Relaxation
Bronchodilator Agents
Ovalbumin
transgelin
Rodentia
Proteins
Phosphorylation
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Yin, L. M., Xu, Y. D., Peng, L. L., Duan, T. T., Liu, J. Y., Xu, Z., ... Yang, Y. Q. (2018). Transgelin-2 as a therapeutic target for asthmatic pulmonary resistance. Science Translational Medicine, 10(427), [eaam8604]. https://doi.org/10.1126/scitranslmed.aam8604

Transgelin-2 as a therapeutic target for asthmatic pulmonary resistance. / Yin, Lei Miao; Xu, Yu Dong; Peng, Ling Ling; Duan, Ting Ting; Liu, Jia Yuan; Xu, Zhijian; Wang, Wen Qian; Guan, Nan; Han, Xiao Jie; Li, Hai Yan; Pang, Yu; Wang, Yu; Chen, Zhaoqiang; Zhu, Weiliang; Deng, Linhong; Wu, Ying Li; Ge, Guang Bo; Huang, Shuang; Ulloa, Luis; Yang, Yong Qing.

In: Science Translational Medicine, Vol. 10, No. 427, eaam8604, 07.02.2018.

Research output: Contribution to journalArticle

Yin, LM, Xu, YD, Peng, LL, Duan, TT, Liu, JY, Xu, Z, Wang, WQ, Guan, N, Han, XJ, Li, HY, Pang, Y, Wang, Y, Chen, Z, Zhu, W, Deng, L, Wu, YL, Ge, GB, Huang, S, Ulloa, L & Yang, YQ 2018, 'Transgelin-2 as a therapeutic target for asthmatic pulmonary resistance', Science Translational Medicine, vol. 10, no. 427, eaam8604. https://doi.org/10.1126/scitranslmed.aam8604
Yin, Lei Miao ; Xu, Yu Dong ; Peng, Ling Ling ; Duan, Ting Ting ; Liu, Jia Yuan ; Xu, Zhijian ; Wang, Wen Qian ; Guan, Nan ; Han, Xiao Jie ; Li, Hai Yan ; Pang, Yu ; Wang, Yu ; Chen, Zhaoqiang ; Zhu, Weiliang ; Deng, Linhong ; Wu, Ying Li ; Ge, Guang Bo ; Huang, Shuang ; Ulloa, Luis ; Yang, Yong Qing. / Transgelin-2 as a therapeutic target for asthmatic pulmonary resistance. In: Science Translational Medicine. 2018 ; Vol. 10, No. 427.
@article{b53a745b222a4cb78e86f18721fcff90,
title = "Transgelin-2 as a therapeutic target for asthmatic pulmonary resistance",
abstract = "There is a clinical need for new bronchodilator drugs in asthma, because more than half of asthmatic patients do not receive adequate control with current available treatments. We report that inhibition of metallothionein-2 protein expression in lung tissues causes the increase of pulmonary resistance. Conversely, metallothionein-2 protein is more effective than -2-agonists in reducing pulmonary resistance in rodent asthma models, alleviating tension in tracheal spirals, and relaxing airway smooth muscle cells (ASMCs). Metallothionein-2 relaxes ASMCs via transgelin-2 (TG2) and induces dephosphorylation of myosin phosphatase target subunit 1 (MYPT1). We identify TSG12 as a nontoxic, specific TG2-agonist that relaxes ASMCs and reduces asthmatic pulmonary resistance. In vivo, TSG12 reduces pulmonary resistance in both ovalbumin- and house dust mite-induced asthma in mice. TSG12 induces RhoA phosphorylation, thereby inactivating the RhoA-ROCK-MYPT1-MLC pathway and causing ASMCs relaxation. TSG12 is more effective than -2-agonists in relaxing human ASMCs and pulmonary resistance with potential clinical advantages. These results suggest that TSG12 could be a promising therapeutic approach for treating asthma.",
author = "Yin, {Lei Miao} and Xu, {Yu Dong} and Peng, {Ling Ling} and Duan, {Ting Ting} and Liu, {Jia Yuan} and Zhijian Xu and Wang, {Wen Qian} and Nan Guan and Han, {Xiao Jie} and Li, {Hai Yan} and Yu Pang and Yu Wang and Zhaoqiang Chen and Weiliang Zhu and Linhong Deng and Wu, {Ying Li} and Ge, {Guang Bo} and Shuang Huang and Luis Ulloa and Yang, {Yong Qing}",
year = "2018",
month = "2",
day = "7",
doi = "10.1126/scitranslmed.aam8604",
language = "English (US)",
volume = "10",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "427",

}

TY - JOUR

T1 - Transgelin-2 as a therapeutic target for asthmatic pulmonary resistance

AU - Yin, Lei Miao

AU - Xu, Yu Dong

AU - Peng, Ling Ling

AU - Duan, Ting Ting

AU - Liu, Jia Yuan

AU - Xu, Zhijian

AU - Wang, Wen Qian

AU - Guan, Nan

AU - Han, Xiao Jie

AU - Li, Hai Yan

AU - Pang, Yu

AU - Wang, Yu

AU - Chen, Zhaoqiang

AU - Zhu, Weiliang

AU - Deng, Linhong

AU - Wu, Ying Li

AU - Ge, Guang Bo

AU - Huang, Shuang

AU - Ulloa, Luis

AU - Yang, Yong Qing

PY - 2018/2/7

Y1 - 2018/2/7

N2 - There is a clinical need for new bronchodilator drugs in asthma, because more than half of asthmatic patients do not receive adequate control with current available treatments. We report that inhibition of metallothionein-2 protein expression in lung tissues causes the increase of pulmonary resistance. Conversely, metallothionein-2 protein is more effective than -2-agonists in reducing pulmonary resistance in rodent asthma models, alleviating tension in tracheal spirals, and relaxing airway smooth muscle cells (ASMCs). Metallothionein-2 relaxes ASMCs via transgelin-2 (TG2) and induces dephosphorylation of myosin phosphatase target subunit 1 (MYPT1). We identify TSG12 as a nontoxic, specific TG2-agonist that relaxes ASMCs and reduces asthmatic pulmonary resistance. In vivo, TSG12 reduces pulmonary resistance in both ovalbumin- and house dust mite-induced asthma in mice. TSG12 induces RhoA phosphorylation, thereby inactivating the RhoA-ROCK-MYPT1-MLC pathway and causing ASMCs relaxation. TSG12 is more effective than -2-agonists in relaxing human ASMCs and pulmonary resistance with potential clinical advantages. These results suggest that TSG12 could be a promising therapeutic approach for treating asthma.

AB - There is a clinical need for new bronchodilator drugs in asthma, because more than half of asthmatic patients do not receive adequate control with current available treatments. We report that inhibition of metallothionein-2 protein expression in lung tissues causes the increase of pulmonary resistance. Conversely, metallothionein-2 protein is more effective than -2-agonists in reducing pulmonary resistance in rodent asthma models, alleviating tension in tracheal spirals, and relaxing airway smooth muscle cells (ASMCs). Metallothionein-2 relaxes ASMCs via transgelin-2 (TG2) and induces dephosphorylation of myosin phosphatase target subunit 1 (MYPT1). We identify TSG12 as a nontoxic, specific TG2-agonist that relaxes ASMCs and reduces asthmatic pulmonary resistance. In vivo, TSG12 reduces pulmonary resistance in both ovalbumin- and house dust mite-induced asthma in mice. TSG12 induces RhoA phosphorylation, thereby inactivating the RhoA-ROCK-MYPT1-MLC pathway and causing ASMCs relaxation. TSG12 is more effective than -2-agonists in relaxing human ASMCs and pulmonary resistance with potential clinical advantages. These results suggest that TSG12 could be a promising therapeutic approach for treating asthma.

UR - http://www.scopus.com/inward/record.url?scp=85039745609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039745609&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aam8604

DO - 10.1126/scitranslmed.aam8604

M3 - Article

AN - SCOPUS:85039745609

VL - 10

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 427

M1 - eaam8604

ER -